STING1 and cancer: While, the role of STING in chronic pain still remains controversial, Donnelly et al. [52] showed that systemic administration of DMXAA (STING activator) reduced spontaneous and ongoing pain; Wang verified that activation of STING in the dorsal root ganglion provides an anti-nociceptive effect in cancer-induced bone pain by directly suppressing nociceptor excitability [28].